Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis

Chirality

Volumn 16, Issue 8, 2004, Pages 520-525

  Lanchote, Vera Lucia ^a   Takayanagui, O M ^a   Mateus, F H ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Albendazole; Enantiomers; Metabolism; Neurocysticercosis; Pharmacokinetics; Renal excretion

Indexed keywords

ALBENDAZOLE; ALBENDAZOLE SULFONE; ALBENDAZOLE SULFOXIDE; AMITRIPTYLINE; BENZAMIDE DERIVATIVE; BROMOCRIPTINE; CARBAMAZEPINE; CLOBAZAM; DEXAMETHASONE; DIAZEPAM; DRUG METABOLITE; LEVODOPA; METOCLOPRAMIDE; PHENOBARBITAL; PHENYTOIN; PROPRANOLOL; RANITIDINE;

ADULT; ARTICLE; CHIRALITY; CLINICAL ARTICLE; CYSTICERCOSIS; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; ENANTIOMER; ENANTIOSELECTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEUROCYSTICERCOSIS; PRIORITY JOURNAL; URINARY EXCRETION;

ADULT; ALBENDAZOLE; FEMALE; HUMANS; KIDNEY; KINETICS; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; NEUROCYSTICERCOSIS; STEREOISOMERISM;

EID: 4544297121     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.20071     Document Type: Article

References (23)

1. Takayanagui OM. Therapy for neurocysticercosis. Expert Rev Neurother 2004;4:129-139.
2. Garcia HH, Evans CAW, Nash TE, Takayanagui OM, White AC, Botero D, Rajshekhar V, Tsang VCW, Schantz PM, Allan JC, Flisser A, Correa D, Sarti E, Friedland JS, Martinez SM, Gonzalez AE, Gilman RH, Del Brutto OH. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002;15:747-756.
3. Rawden HC, Kokwaro GO, Ward SA, Edwards G. Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 2000;49:313-322.
4. Souhaili-El Amri H, Mothe O, Totis M, Masson C, Batt AM, Delatour P, Siest G. Albendazole sulfonation by rat liver cytochrome P-450c. J Pharmacol Exp Ther 1988;246:758-764.
5. Villaverde C, Alvarez AI, Redondo P, Voces J, Del Estal JL, Prieto JG. Small intestinal sulphoxidation of albendazole. Xenobiotica 1995;25:433-441.
6. Moroni P, Buronfosse T, Longin-Sauvageon C, Delatour P, Benoit E. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monoxygenases from rat liver microsomes. Drug Metab Dispos 1995;23:160-164.
7. Delatour P, Benoit E, Besse S, Boukraa A. Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs and rats. Xenobiotica 1991;21:217-221.
8. Marques MP, Takayanagui OM, Bonato PS, Santos SRCJ, Lanchote VL. Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. Chirality 1999;11:218-223.
9. Delatour P, Benoit E, Caude M, Tambute A. Species differences in the generation of the chiral sulfoxide metabolite of albendazole in sheep and rats. Chirality 1990;2:156-160.
10. Delatour P, Garnier F, Benoit E, Caude I. Chiral behaviour of the metabolite albendazole sulphoxide in sheep, goats and cattle. Res Vet Sci 1991;50:134-138.
11. Cotting J, Zeugin T, Steiger U, Reichen J. Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis. Eur J Clin Pharmacol 1990;38:605-608.
12. Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 1988;34:315-317.
13. Jung H, Hurtado M, Sanchez M, Medina MT, Sotelo J. Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. J Clin Pharmacol 1992;32:28-31.
14. Takayanagui OM, Lanchote VL, Marques MPC, Bonato PS. Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Ther Drug Monit 1997;19:51-55.
15. Lanchote VL, Garcia FS, Dreossi SAC, Takayanagui OM. Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. Ther Drug Monit 2002;24:338-345.
16. Takayanagui OM, Bonato PS, Dreossi SAC, Lanchote VL. Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. Br J Clin Pharmacol 2002;54:125-130.
17. Lanchote VL, Marques MPC, Takayanagui OM, Carvalho R, Bonato PS. Simultaneous determination of albendazole sulfoxide enantiomers and albendazole sulfone in plasma. J Chromatogr B 1998;709:273-279.
18. Garcia JJ, Bolás-Fernández F, Torrado JJ. Quantitative determination of albendazole and its main metabolites in plasma. J Chromatogr B 1999;723:265-271.
19. Kitzman D, Cheng KJ, Fleckenstein L. HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. J Pharm Biomed Anal 2002;30:801-813.
20. Paias FO, Lanchote VL, Takayanagui OM, Bonato PS. Enantioselective analysis of albendazole sulfoxide in cerebrospinal fluid by capillary electrophoresis. Electrophoresis 2001;22:3263-3269.
21. Bonato PS, Lanchote VL, Takayanagui OM. Simultaneous liquid chromatography-tandem mass spectrometric determination of albendazole sulfoxide and albendazole sulfone in plasma. J Chromatogr B 2003;783:237-245.
22. Marriner SE, Morris DL, Dickson B, Bogan JA. Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 1986;30:705-708.
23. Sánches M, Suástegui R, Gonzáles-Esquivel D, Sotelo J, Jung H. Pharmacokinetic comparison of two albendazole dosage regimens in patients with neurocysticercosis. Clin Neuropharmacol 1993;16:77-82.